Prolia or Ranmark Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Prolia or Ranmark market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historic period can be attributed to factors such as the increasing prevalence of osteoporosis, growing awareness and improved diagnosis, the efficacy and safety profile for expanded indications, a rising aging population, and advancements in research and development.

The growth anticipated in the forecast period can be attributed to factors such as increased healthcare investments in drug discovery and development, more approvals for medications, the growth of generic drugs, a rising prevalence of postmenopausal disorders, and greater adoption of bone health diagnostics. Key trends during this period include advancements in biologic therapies, technological innovations in drug delivery, integration of digital health, progress in personalized medicine, and the expansion of telemedicine and remote monitoring.

The rising prevalence of osteoporosis is expected to drive the growth of the Prolia or Ranmark market. Osteoporosis is a systemic skeletal disease characterized by low mineral density and the deterioration of bone tissue, which increases bone fragility and the risk of fractures. The prevalence of osteoporosis is linked to factors such as aging, hormonal imbalances, genetic predisposition, insufficient calcium and vitamin D intake, physical inactivity, smoking, and excessive alcohol consumption. Prolia or Ranmark (denosumab) helps manage osteoporosis by inhibiting osteoclast activity, which is responsible for bone resorption, thereby increasing bone density and reducing the risk of fractures. For example, in June 2024, the Australian Institute of Health and Welfare reported that approximately 853,600 people in Australia were living with osteoporosis or osteopenia in 2022. Furthermore, osteoporosis contributed to 2,659 deaths, or 10.2 deaths per 100,000 population, in 2022. As a result, the increasing prevalence of osteoporosis is fueling the growth of the Prolia or Ranmark market.

The growing incidence of bone cancer is also expected to drive the growth of the Prolia or Ranmark market. Bone cancer is a type of cancer that originates in the bone cells, and it can be either primary, starting in the bone, or secondary, spreading from other parts of the body. The rise in bone cancer cases is attributed to factors such as genetic predisposition, radiation exposure, and certain inherited conditions. Prolia or Ranmark (denosumab) assist in managing bone cancer by inhibiting osteoclast activity, which reduces bone resorption and helps prevent fractures. This also slows the progression of bone metastases in cancer patients. For instance, in 2023, the American Cancer Society reported that the estimated number of new cancer cases in bones and joints increased to 3,970, compared to 3,910 in 2022. Therefore, the growing incidence of bone cancer is contributing to the market's growth.

In June 2024, Alvotech, a biotechnology company based in Luxembourg, expanded its collaboration with Stada Arzneimittel AG, a pharmaceutical company in Germany, to develop a new biosimilar called AVT03. This biosimilar is intended as a treatment for conditions such as osteoporosis and bone cancer and references Amgen's Prolia and Xgeva (denosumab). Stada Arzneimittel AG is involved in providing biosimilar products.

Major companies operating in the prolia or ranmark market are Amgen Inc. and Daiichi Sankyo Co. Ltd.

North America was the largest region in the prolia or ranmark market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in prolia or ranmark report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the prolia or ranmark market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Prolia (also known as Ranmark) is a prescription medication containing denosumab, which works by inhibiting RANKL to reduce bone resorption. By binding to RANKL, it prevents its interaction with osteoclasts, the cells responsible for bone breakdown. This action increases bone density, strengthens bones, and reduces the risk of fractures. Prolia is used to treat osteoporosis and bone metastases in cancer patients.

The main indications for Prolia include osteoporosis and bone metastasis. Osteoporosis is a condition where bones become weakened, leading to an increased risk of fractures, particularly in older adults and postmenopausal women. The drug is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is used by a broad range of end users, including hospitals, specialty clinics, homecare providers, and ambulatory surgical centers.

The prolia or ranmark market research report is one of a series of new reports that provides prolia or ranmark market statistics, including the prolia or ranmark industry global market size, regional shares, competitors with the prolia or ranmark market share, detailed prolia or ranmark market segments, market trends, and opportunities, and any further data you may need to thrive in the prolia or ranmark industry. This prolia or ranmark market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The prolia or ranmark market consists of sales of prolia subcutaneous injections, 60 mg and 120 mg and ranmark subcutaneous injection 120 mg. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.